Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus Knocks Out One Humira Patent But Others Block Biosimilars

Executive Summary

Patent Trial and Appeal Board invalidates patent on method to treat rheumatoid arthritis; next hurdle is overcoming formulation patents that do not expire until 2022.

Advertisement

Related Content

PTAB Tosses Two More Humira Patents; Will Supreme Court Eliminate IPR Proceeding?
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel